Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it ...
In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...
The rate of relapse among patients with TP53-mutated myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) was similar among those who underwent allogeneic hematopoietic stem cell transplant ...
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning ...
Brukinsa showed superior PFS and ORR compared to Rituxan in CLL/SLL patients, with a 71% risk reduction in progression or death. Brukinsa's efficacy was consistent across various risk factors, ...
In a recent perspective published in the journal Cell Death and Differentiation, researchers in France, Germany, and Sweden discussed the unique mutational spectrum of the transformation-related ...
Researchers in Class of 1942 Professor of Chemistry Matthew D. Shoulders' lab have uncovered a sinister hidden mechanism that ...
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study Authors retain all rights in any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results